News and Updates

This article was written by Amanda Gilchrist, a Participant Advisory Council Member (PAC), a Clinical Trial Education Volunteer, and Breakthrough T1D supporter. Amanda’s story details her family’s type 1 diabetes (T1D) journey, why clinical trial participation is important to her, and her experience in the PAC. The views expressed by the author are her own […]

Islet cell therapies for type 1 diabetes (T1D) replace destroyed insulin-producing beta cells with functional cells that allow the body to make insulin again. To ensure there are enough islet cells for everyone with T1D who wants them, Breakthrough T1D is prioritizing manufactured cell therapies, which can be made in large quantities in a laboratory, […]

Taking care of your mental health with type 1 diabetes is just as important as managing your blood sugar and taking your insulin.

It was identified in the late 1960s. Since then, studies have shown that it is a biomarker for beta cell function. In other words, it’s a measure of beta cell health and insulin production. If it’s low (or you have none), it indicates that your pancreas is producing little or no insulin. There was even […]

Breakthrough T1D is focused on developing drugs, or disease-modifying therapies (DMTs), that change the course of T1D for everyone affected by it—and those yet to be. That means slowing or halting the progression of the disease, preventing it from ever occurring, and reversing it entirely through immune therapies and beta cell therapies.  Note: To enlarge the image below, left click […]

Breakthrough T1D is back from Barcelona! The final two days of ATTD were jam-packed with more incredible updates across all areas of our mission. Breakthrough T1D staff chaired and participated in many sessions—including Breakthrough T1D Senior Vice President of Research, Esther Latres, Ph.D.; Vice President of Medical Affairs Anastasia Albanese O’Neill, Ph.D., APRN, CDCES; Senior […]

Greetings from Barcelona, Spain! From March 11–14, 2026, the world’s leading type 1 diabetes (T1D) researchers, healthcare professionals, and industry partners gathered to share groundbreaking advances in T1D science—and Breakthrough T1D–supported work (and staff) were front and center. Below is everything you need to know from the first two days of this remarkable conference, including […]

Tzield is the first approved disease-modifying therapy for type 1 diabetes, but Breakthrough T1D will make sure it’s not the last.

One of our most promising avenues toward cures for type 1 diabetes (T1D) is cell therapies. Cell therapies replace destroyed beta cells with functional, insulin-producing cells to restore insulin therapy independence. Right now, there are nearly a dozen cell therapies in clinical testing—and OPF-310 is one of them. OPF-310 cells are derived from porcine (pig) […]

This article was written by Alecia Wesner (pictured above, right), a Participant Advisory Council (PAC) member, a Clinical Trial Education Volunteer, and long-time Breakthrough T1D supporter. Alecia’s story details her lived experiences with type 1 diabetes, participation in clinical trials, and her journey to joining the PAC. The views expressed by the author are her […]